A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues
Lata T. Gooljarsingh(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Marc R. Arnone(GlaxoSmithKline (United States)), Michael Grooms(Protein Express (United States)), Hong Zhang(State Administration of Traditional Chinese Medicine of the People's Republic of China), Zhihong Lai(South College), Kyung Johanson(South College), Robert H. Sinnamon(GlaxoSmithKline (United States)), Robert B. Kirkpatrick(Protein Express (United States)), Robert A. Copeland(Unknown), Tia Lewis(Protein Express (United States)), John J. Kerrigan(Protein Express (United States)), Kang Yan, Christine Fernandes(United States Military Academy), Alastair J. King(Charles River Laboratories (Netherlands))
Cited by 119
Related Papers
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
|Journal of Biological Chemistry|1998|3k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848